Premium Nahrungsergänzungsmittel | artgerecht

BiTE Antibody: Bispecific T-Cell Engager Explained

BiTE antibodies are bispecific antibodies that simultaneously bind T-cells and cancer cells, triggering targeted tumor destruction. They represent a major advance in cancer immunotherapy.

Regular tips about health Regular tips about health

Things worth knowing about "BiTE Antibody"

BiTE antibodies are bispecific antibodies that simultaneously bind T-cells and cancer cells, triggering targeted tumor destruction. They represent a major advance in cancer immunotherapy.

What are BiTE Antibodies?

BiTE antibodies (Bispecific T-cell Engagers) are a class of engineered antibodies designed to redirect the immune system against cancer cells. Unlike conventional antibodies that recognize only one target, BiTE antibodies have two distinct binding arms: one arm binds to a specific surface antigen on tumor cells, while the other arm binds to the CD3 protein on cytotoxic T-lymphocytes (killer T-cells). By bridging these two cell types, BiTE antibodies bring T-cells into direct proximity with cancer cells, initiating their destruction.

Mechanism of Action

The mechanism of action of BiTE antibodies can be broken down into key steps:

Binding to tumor cells: One arm of the BiTE antibody recognizes a tumor-specific surface antigen, such as CD19 on B-cell leukemia cells.
Binding to T-cells: The second arm simultaneously engages the CD3 complex on T-cells.
Immunological synapse formation: The spatial proximity of T-cell and tumor cell creates an immunological synapse.
T-cell activation and cytotoxicity: The T-cell becomes activated and releases cytotoxic substances (e.g., perforins and granzymes) that destroy the cancer cell.

A key feature of this mechanism is that T-cell activation occurs independently of the classical T-cell receptor-MHC interaction, meaning T-cells can be activated even without prior sensitization to the tumor antigen.

Structure

BiTE antibodies are relatively small protein molecules. They consist of two single-chain variable fragments (scFv domains) connected by a short peptide linker. Due to their small size, they are rapidly cleared by the kidneys, which necessitates continuous intravenous infusion during treatment.

Clinical Applications

BiTE antibodies are primarily used in hematologic oncology for blood cancers and related conditions. The most well-known approved BiTE antibody is blinatumomab (trade name: Blincyto), which targets the CD19 antigen on B-cells and is approved for the treatment of acute lymphoblastic leukemia (ALL). Other current and emerging applications include:

Acute lymphoblastic leukemia (ALL): Particularly in relapsed or refractory cases.
Multiple myeloma: Newer BiTE antibodies target antigens such as BCMA or CD38.
Other lymphoid malignancies: Ongoing research in non-Hodgkin lymphoma and other B-cell disorders.

Side Effects

As with all immunotherapies, BiTE antibodies can cause significant side effects. The most important include:

Cytokine release syndrome (CRS): A systemic inflammatory response from massive T-cell activation, presenting with fever, chills, low blood pressure, and organ dysfunction.
Neurological adverse effects: Confusion, seizures, and encephalopathy have been reported.
Increased infection risk: The therapy often leads to B-cell aplasia, raising the risk of infections.
General symptoms: Fatigue, nausea, headache, and fever.

Advantages Over Other Immunotherapies

Compared to other cancer therapies, BiTE antibodies offer several important advantages:

They harness the natural cytotoxic power of the patient's own T-cells.
They are effective even against tumor cells that express low or no MHC-I molecules, making them invisible to conventional T-cell responses.
Compared to CAR-T cell therapies, they are more rapidly available since no patient-specific cell manufacturing is required.

Current Research and Outlook

The development of BiTE antibodies is advancing rapidly. In addition to refinements of existing molecules, research is focused on longer-lived formats (half-life extended BiTEs) that would allow subcutaneous administration. Furthermore, BiTE antibodies are being investigated against solid tumors, which would significantly broaden their therapeutic scope.

References

Nagorsen D, Bargou R, Röttinger M, Kufer P, Baeuerle PA, Zugmaier G. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leukemia & Lymphoma. 2009;50(6):886-891.
Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. The Lancet Oncology. 2015;16(1):57-66.
European Medicines Agency (EMA). Blincyto (blinatumomab) - Product Information and Approval Documents. Available at: https://www.ema.europa.eu

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.